Industry
Coverage and analysis in industry from the Peptidings newsroom.
Novo Nordisk Q1: Wegovy Pill Hits 1.3 Million Prescriptions in Its First Quarter
Novo Nordisk's Q1 2026 results: Wegovy pill 1.3M prescriptions, 65% of all new US GLP-1 starts, $15.17B revenue beat, guidance raised. The oral GLP-1 era arrives.
GHK-Cu Just Crossed Into Mainstream Beauty. The Evidence for Injectable Use Hasn’t Caught Up.
GHK-Cu search volume is up 1,016% year-over-year as the beauty industry pivots to copper peptides. The topical evidence is real. The injectable evidence isn't.
Lilly’s $19.8 Billion Q1: Mounjaro Doubles, Foundayo Ships, TRIUMPH-1 Imminent
Eli Lilly Q1 2026 earnings: $19.8B revenue (+56%), Mounjaro $8.7B (+125%), Zepbound $4.16B, raised guidance to $82-85B, Foundayo launched, TRIUMPH-1 imminent.
Viking Q1 2026: VANQUISH Fully Enrolled, Oral VK2735 Slips, VK3019 Comes Forward
Viking Therapeutics Q1 2026: VANQUISH Phase 3 fully enrolled at 5,500+ patients, oral VK2735 Phase 3 pushed to Q4, amylin agonist VK3019 IND filed with primate data.
Viking Therapeutics, Amgen, and the Next-Generation Obesity Pipeline
While Eli Lilly consolidates its lead in the obesity therapeutics market, a second wave of companies is advancing candidates that […]
Novo Nordisk’s CagriSema Fails to Beat Tirzepatide in Head-to-Head Trial
Novo Nordisk’s next-generation weight-loss candidate CagriSema — a fixed-ratio combination of semaglutide and the amylin analog cagrilintide — failed to demonstrate superiority […]